- Stocks
- Healthcare
- NASDAQ: FIXX

Price (delayed)

$6.86

Market cap

$391.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.03

Enterprise value

$300.73M

FIXX's EPS is up by 28% from the previous quarter and by 22% YoY

FIXX's net income is up by 27% since the previous quarter and by 18% year-on-year

FIXX's quick ratio is down by 21% year-on-year but it is up by 11% since the previous quarter

FIXX's equity is down by 11% year-on-year but it is up by 2.5% since the previous quarter

What are the main financial stats of FIXX

Market
Valuations
Earnings

Shares outstanding

57.08M

Market cap

$391.6M

Enterprise value

$300.73M

Price to earnings (P/E)

N/A

Price to book (P/B)

1.72

Price to sales (P/S)

11

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

9.57

Revenue

$31.42M

EBIT

-$94.44M

EBITDA

-$85.3M

Free cash flow

-$100.83M

Per share
Balance sheet
Liquidity

EPS

-$2.03

Free cash flow per share

-$2

Book value per share

$3.98

Revenue per share

$0.62

TBVPS

$4.66

Total assets

$234.7M

Total liabilities

$33.87M

Debt

$14.82M

Equity

$200.83M

Working capital

$173.84M

Debt to equity

0.07

Current ratio

10.76

Quick ratio

10.67

Net debt/EBITDA

1.07

Margins
Efficiency
Dividend

EBITDA margin

-271.5%

Gross margin

100%

Net margin

-300.6%

Operating margin

-302%

Return on assets

-38.3%

Return on equity

-49.6%

Return on invested capital

-126.7%

Return on capital employed

-43.5%

Return on sales

-300.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Homology Medicines stock price performed over time

Intraday

-5.51%

1 week

-4.32%

1 month

2.54%

1 year

-56.53%

YTD

-39.24%

QTD

-27.1%

How have Homology Medicines's revenue and profit performed over time

Revenue

$31.42M

Gross profit

$31.42M

Operating income

-$94.88M

Net income

-$94.44M

Gross margin

100%

Net margin

-300.6%

FIXX's net margin has surged by 95% year-on-year and by 94% since the previous quarter

The operating margin has soared by 95% YoY and by 94% from the previous quarter

FIXX's net income is up by 27% since the previous quarter and by 18% year-on-year

The operating income is up by 27% since the previous quarter and by 22% year-on-year

What is Homology Medicines's growth rate over time

What is Homology Medicines stock price valuation

P/E

N/A

P/B

1.72

P/S

11

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

9.57

FIXX's EPS is up by 28% from the previous quarter and by 22% YoY

The P/B is 39% below the last 4 quarters average of 2.8

FIXX's equity is down by 11% year-on-year but it is up by 2.5% since the previous quarter

The P/S is 94% less than the last 4 quarters average of 184.2

How efficient is Homology Medicines business performance

Homology Medicines's return on invested capital has shrunk by 124% YoY but it has increased by 22% QoQ

FIXX's ROS has soared by 95% YoY and by 94% from the previous quarter

The return on equity has increased by 24% since the previous quarter but it has declined by 10% year-on-year

The ROA has grown by 23% from the previous quarter but it has contracted by 4.4% YoY

What is FIXX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for FIXX.

How did Homology Medicines financials performed over time

The total liabilities has plunged by 50% from the previous quarter and by 46% YoY

FIXX's quick ratio is down by 21% year-on-year but it is up by 11% since the previous quarter

FIXX's debt is 93% smaller than its equity

FIXX's debt is down by 14% year-on-year and by 4% since the previous quarter

Homology Medicines's debt to equity has decreased by 13% from the previous quarter and by 13% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.